Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling